Merck Acquisition of Medco Case Study John X Devry University – Keller Graduate School of Management Finance 561 Professor May 22‚ 2011 Table of Contents Abstract………………………………………………………………………………………p.g. 3 Company backgrounds……………………………………………………….………………p.g. 3 Merck & Co.‚ Inc. ………………………………………..…………………….…....p.g. 3 Medco Containment Services Inc. ............................……..…………………………p.g. 4 Reasons for Mergers…………………………………………………………………………p.g. 5 Economies of Scale………………………………………………………………….
Premium Mergers and acquisitions Marketing
CASE 5.1: MERCK ACQUISITION OF MEDCO Abstract Corporate mergers and acquisitions (M&A) have become popular across the globe during the last two decades due to globalization‚ liberalization‚ technological developments‚ and competitive business environment (Fisher & Siburg‚ 2009). The synergistic gains from M&A may result from efficient management‚ economies of scale‚ profitable use of assets‚ exploitation of market power‚ and the use of complementary resources (Mitchell
Premium Pharmacology Pharmaceutical industry Pharmacy
You Decide Assignment on Merck’s Acquisition of Medco By Zankhana Desai FIN 561- Mergers and Acquisition Professor: Yvan Nezerwe Keller Graduate School of Management Table of Contents C5.1.0 Executive Summary…………………………………………….3 C5.1.1 The Major Driving Force of the Merck-Medco Acquisition.. 3-4 C5.1.2 The Role of PBM Companies……………………………….. 4-5 C5.1.3 Utilization of Medco’s Database……………………………. 5-6 C5.1.4 Competitive Reactions to Merck- Medco Acquisition ……. 6 C5.1.5 SWOT Analysis……………………………………………
Premium Management Marketing Strategic management
Case #1: Merck and River Blindness MGT 597: Leadership Ethics Dr. Brandon Randolph-Seng Javiaur Harmon: Winter Mini 2014 - 2015 1. Think about the definition stakeholders—any parties with a stake in the organization’s actions or performance. Who are the stakeholders in this situation? How many can you list? On what basis would you rank them in importance? The stakeholders in this situation were the employees (research scientists doing the R&D)‚ Merck‚ and the target audience which
Premium Value system Risk Intrinsic value
Pharmaceuticals: Merck Sustaining Long-term Advantage Through Information Technology Hiroshi Amari Working Paper No. 161 Working Paper Series Center on Japanese Economy and Business Columbia Business School December 1998 Columbia-Yale Project: Use of Software to Achieve Competitive Advantage PHARMACEUTICALS: MERCK Sustaining Long-term Advantage Through Information Technology Prepared by Hiroshi Amari Research Associate‚ Yale University William V. Rapp and Hugh T. Patrick Co-principal
Premium Clinical trial Pharmaceutical industry Drug development
decision (not covered in class?) Based on the pyramid of social responsibility‚ Merck is required to be profitable (base). Since the research of development will never be profitable to shareholders Merck should do develop the drug. Based on Merck’s actual value system‚ it wants to be ethical and even be a good corporate citizen. So Merck should conduct the research. Question 8 - If you were the senior executive of Merck‚ what would you do? (Open question) I would make assessment of the potential costs
Premium Social responsibility Corporation Business ethics
The Acquisition between Merck and Schering-Plough Introduction On March 9‚ 2009‚ Merck & Co.‚ Inc. and Schering-Plough Corporation announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine‚ under the name Merck in a stock and cash transaction. As the two companies’ combined 2008 revenues were $47 billion. The deal officially closed on November 3‚ 2009. Background of the two parties Merck & Co. (NYSE:
Premium
Case Study: Merck Acquisition of Medco Professor Daniel Weiss FI561 January 23‚ 2011 Case Study: Merck Acquisition of Medco Abstract The purpose of this case study is to determine whether it would be beneficial to merge Merck Corporation with Medco Containment Services Incorporated. The merger and acquisition between the world’s largest drug manufacturer and the largest prescription benefits management company (PBM) and marketer of mail order medicines in the United States would result
Premium Mergers and acquisitions Due diligence
1. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? Merck had a 14% increase in sales between 1997 and 1998 and 22% increase in sales from 1998 – 1999‚ and a 13% annual increase in earnings over the same period. Merck’s business strategy consists of two parts: (1) developing and marketing new drugs through internal research‚ and (2) developing partnerships with smaller biotechnology companies. Since 1995‚ Merck had launched
Premium Expected value License Money
competitors were gaining ground by being placed on Medco formularies (Pg.16). If one of these companies were to get complete control‚ it could replace most of Merck’s products with its own. In a way‚ this acquisition was an investment to properly position Merck in an unpredictable future. If this future held a system in which the most drugs were sold through PBMs‚ or not‚ Merck would be positioned to continue their successful business. As one Merck-Medco put it “Our business is constantly changing.”
Premium Health care Medicine Health insurance